Skip to main content
OpenTrials
Recruiting

NCT Number: NCT05213806

WithHolding Enteral Feeds Around Blood Transfusion (International)

The WHEAT International trial is a comparative effectiveness trial exploring whether withholding enteral feeds around the time of blood transfusion in very premature infants (<30 weeks) will reduce the occurrence of Necrotizing Enterocolitis (NEC). Currently both continued feeding and withholding feeding are approved care practices. The current study will randomize infants from Neonatal Intensive Care Units (NICUs) across Canada and the United Kingdom (UK) into one of the two care approaches (withholding or continued feeds) to determine if any significant outcomes are found.

Recruiting

Interested in participating?

Request Info

Key information

Age range

Up to 30 week

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

IWK Health, Halifax, Nova Scotia, Canada

Loading trial locations.

About this study

BACKGROUND: Necrotizing enterocolitis (NEC) is a devastating disease that affects mostly the intestine of premature infants. The wall of the intestine is invaded by bacteria, which cause local infection and inflammation that can ultimately destroy the wall of the bowel (intestine). NEC is among the most potentially devastating neonatal diseases and has a mortality of up to 33%, the most severe form (requiring surgery or resulting in death) affects about 5% of infants born at less than 30 gestational weeks; survivors are at high risk of long-term health and developmental problems. Prevention of NEC has been identified as one of the most important research uncertainties in the field of preterm birth. A temporal association between red cell transfusion and the subsequent development of the disease is well described. This 'transfusion-associated NEC' may also be more severe with higher mortality. Very preterm or extremely low birth weight infants are among the most frequently transfused patients: between 56% and 90-95% have at least one transfusion, and those transfused received an average of 5 transfusions in their neonatal stay. Withholding milk feeds during red cell transfusion may reduce the risk of NEC by decreasing postprandial mesenteric ischemia but there may be harmful effects of pausing enteral feeds. However, due to a lack of good quality evidence, there is no consensus regarding the optimal feeding strategy during a blood transfusion.

Both comparator pathways of care are standard practice in Canada and the UK; the WHEAT trial is a comparative effectiveness trial. The two care pathways that will be compared are:

  • Withholding Feeds Around Transfusion: All enteral feeds will be discontinued (the infant will be placed nil by mouth) for 4 hours prior to packed red cell transfusion, during the packed red cell transfusion and until 4 hours post packed red cell transfusion.
  • Continuing Feeds Around Transfusion: Enteral feeds will continue to be given prior, during and after the packed red cell transfusion, in the manner in which they were being given prior to the decision to transfuse.

Infants will remain allocated to the same care pathway until 34(+6) weeks(+days) gestational age.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Preterm birth at <30+0 gestational weeks + days

Exclusion criteria

  • Parent(s) opt-out of trial participation.
  • Packed red cell transfusion with concurrent enteral feeds prior to enrolment. (Infants who have received a packed red cell transfusion while nil-by-mouth are eligible; or minimal enteral nutrition (<15 ml/kg/day feeds) at the time of transfusion; defined as before, during and for at least 4 hours after transfusion, are eligible.
  • Infants who are not being fed at the time of randomization (<15ml/kg) or where enteral feeding is contraindicated [e.g. Major congenital abnormality of the gastrointestinal tract (GIT)].
  • Previous episode of NEC Bell stage 2 or higher or SIP prior to first study packed cell transfusion.

Treatment and study plan

Withholding feeds around transfusion

Other

Withholding enteral feeds for preterm infants (<30 weeks) around the time of blood transfusions to determine if any impact on the development and/or severity of Necrotizing Enterocolitis.

Continued feeds around transfusion

Other

Continued enteral feeds

Primary outcomes

  1. NEC Stage II

    Time frame: From randomization to 40 weeks postmenstrual age

    Stage II or greater NEC recorded after the first trial blood transfusion; defined according to the modified Bell staging criteria: based on clinical features and abdominal imaging findings, or on surgical or histological findings of NEC.

Secondary outcomes

  1. Severe NEC

    Time frame: From randomization to 40 weeks postmenstrual age

    Histologically or surgically confirmed or recorded on the death certificate. These infants will be identified as described in Battersby et al. which will include infants recorded as being transferred for surgery.

  2. Death

    Time frame: From randomization to 40 weeks postmenstrual age

    All-cause mortality

  3. Late onset sepsis

    Time frame: From randomization to 40 weeks postmenstrual age

    Culture positive sepsis, onset after 72 hours of life

  4. Number of days with a central venous line in situ

    Time frame: From birth to date of discharge home

    Number of days with a central venous line in situ

  5. Number of central line associated bloodstream infections

    Time frame: From randomization to 40 weeks postmenstrual age

    Number of central line associated bloodstream infections: Positive blood culture confirmed bloodstream infection

  6. Duration of any parenteral nutrition in days

    Time frame: From birth to 40 weeks postmenstrual age

    Duration of any parenteral nutrition in days

  7. Growth

    Time frame: At date of discharge home

    Weight and head circumference z score.

  8. Spontaneous Intestinal Perforation

    Time frame: From randomization to 40 weeks postmenstrual age

    Histologically or surgically confirmed or recorded in the death certificate.

  9. Duration of hospital stay

    Time frame: From birth to date of discharge home

    Total duration of neonatal care in days including all levels of care (intensive care, high dependency care, special care and ordinary care)

  10. Bronchopulmonary Dysplasia (BPD)/Chronic Lung Disease

    Time frame: At 36 weeks postmenstrual age

    Requiring respiratory support at 36 weeks gestation

  11. Retinopathy of prematurity (ROP)

    Time frame: From randomization to 40 weeks postmenstrual age

    ROP requiring treatment

  12. Severe Brain Injury

    Time frame: At 40 weeks postmenstrual age

    Intraventricular haemorrhage (IVH) grade 3 or 4 or cystic periventricular leukomalacia (PVL)

Study contacts

Contact information is provided by the study sponsor or research team.

Cari-Lee Carnell

CONTACT

[email protected]

9024706630

Tara Hatfield

CONTACT

[email protected]

9024706630

Sponsors and collaborators

Lead sponsor

IWK Health Centre

Other

Collaborators

  • Canadian Institutes of Health Research (CIHR)
  • Imperial Clinical Trials Unit (ICTU)
  • Imperial College London

Registry information

Official study title

The WHEAT International Trial: WithHolding Enteral Feeds Around Red Cell Transfusion to Prevent Necrotizing Enterocolitis in Preterm Neonates: an International, Multi-centre, Randomized Controlled Trial

Acronym: WHEAT

Important dates

Study start
2022
Primary completion
2027
Study completion
2027
First posted
Jan 28, 2022
Registry last updated
Apr 24, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.